These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38751545)

  • 1. A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer.
    Yang L; Chen Y; Wang N; Han W
    Transl Breast Cancer Res; 2022; 3():4. PubMed ID: 38751545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP; Generali D
    Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
    Raheem F; Ofori H; Simpson L; Shah V
    Ann Pharmacother; 2022 Feb; ():10600280211073322. PubMed ID: 35135362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
    Fung S; Blair HA
    Target Oncol; 2023 Mar; 18(2):287-294. PubMed ID: 36826463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
    Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
    Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer.
    O'Keefe K; Desai NV; Tan AR
    Breast Cancer (Dove Med Press); 2024; 16():517-527. PubMed ID: 39224861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
    Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
    Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho AD; Rybowski S
    Drugs Real World Outcomes; 2023 Dec; 10(4):589-603. PubMed ID: 37775689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
    Wu Y; Zhang Y; Pi H; Sheng Y
    Cancer Manag Res; 2020; 12():3477-3487. PubMed ID: 32523378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
    Abdel-Razeq H; Sharaf B
    Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical discovery and development of abemaciclib used to treat breast cancer.
    Wright MD; Abraham MJ
    Expert Opin Drug Discov; 2021 May; 16(5):485-496. PubMed ID: 33280445
    [No Abstract]   [Full Text] [Related]  

  • 16. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
    Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
    Front Oncol; 2021; 11():810023. PubMed ID: 35223458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Gene Panel Associated With Abemaciclib Utility in
    Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Lloyd MR; Kambadakone A; Spring LM; Micalizzi DS; Onozato ML; Che D; Nayar U; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Han HS; Iafrate AJ; Ryan LY; Juric D; Moy B; Ellisen LW; Maheswaran S; Wagle N; Haber DA; Bardia A; Wander SA
    JCO Precis Oncol; 2023 May; 7():e2200532. PubMed ID: 37141550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.